Lipoprotein‐Based Nanocatalyst Enables Targeted Treatment of APAP‐Induced Liver Injury via Enhanced Macropinocytosis
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yaoxing Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Road Number Two, Shanghai, 200025, C…. Hauptthemen laut MEDLINE: Cerium, Chemical and Drug Induced Liver Injury, Acetaminophen, Pinocytosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Development Foundation, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Drug‐induced liver injury (DILI), predominantly caused by acetaminophen (APAP) overdose, is characterized by excessive reactive oxygen species (ROS) production and subsequent hepatocyte necrosis. Although N ‐acetylcysteine (NAC) remains the only approved treatment, its effectiveness is limited by a narrow therapeutic time window and reduced efficacy in advanced cases. To address these limitations, an innovative therapeutic approach is developed utilizing ceria's antioxidant properties. In this study, a reconstituted high‐density lipoprotein‐encapsulated ceria nanocatalyst (CeO 2 ‐rHDL) is engineered to overcome the aggregation tendency and targeting limitation of naked ceria nanoparticles. These findings revealed that CeO 2 ‐rHDL enters hepatocytes through macropinocytosis, a process synergistically enhanced by both APAP and NAC, facilitating efficient liver targeting. The nanocatalyst demonstrated remarkable therapeutic efficacy by restoring mitochondrial function through ROS reduction. When combined with NAC, CeO 2 ‐rHDL significantly improved survival outcomes in DILI mice. This lipoprotein‐based nanocatalyst system represents a promising therapeutic strategy for DILI treatment, offering enhanced targeting capabilities and improved therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Road Number Two, Shanghai, 200025, China.
- Department of Pharmacology and Chemical Biology, Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 20…
ORCID-Profile: Yaoxing Chen, Gan Jiang, Xiaoling Gao, Qing Xie
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Development Foundation
- Shanghai Rising-Star Program
- Shanghai Municipal Education Commission
- Key Technologies Research and Development Program
- Ruijin Hospital
- Shanghai Municipal Health Commission
Zitieren
APA
Chen, Y., Jiang, G., Huang, Y., Song, S., Fu, H., Du, B., Xiao, Y., Li, P., Shi, K., Huang, Y., Song, Q., Gao, X., & Xie, Q. (2025). Lipoprotein‐Based Nanocatalyst Enables Targeted Treatment of APAP‐Induced Liver Injury via Enhanced Macropinocytosis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500507
Vancouver
Chen Y, Jiang G, Huang Y, Song S, Fu H, Du B, et al. Lipoprotein‐Based Nanocatalyst Enables Targeted Treatment of APAP‐Induced Liver Injury via Enhanced Macropinocytosis. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500507
BibTeX
@article{Chen2025,
author = {Chen, Yaoxing and Jiang, Gan and Huang, Yan and Song, Shuying and Fu, Haoshuang and Du, Bingying and Xiao, Yuelin and Li, Peiying and Shi, Kexin and Huang, Yukun and Song, Qingxiang and Gao, Xiaoling and Xie, Qing},
title = {Lipoprotein‐Based Nanocatalyst Enables Targeted Treatment of APAP‐Induced Liver Injury via Enhanced Macropinocytosis},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500507}
}
EUVIMED